Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos' financial outlook, restructuring activities and estimated cash outlook as reported by ...

A new groundbreaking study revealed that Remibrutinib showed promising results in treating chronic spontaneous urticaria.A recent study published in the New England Journal of Medicine outlined the ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...

Xyzal (levocetirizine) and Zyrtec (cetirizine) are over-the-counter (OTC) allergy medications. Learn about their key ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Skin reactions can be alarming, especially when they appear suddenly. Many people struggle to tell the difference between ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...